Clinical TrialsA slight delay in the timing of the Phase 3 study initiation for lead asset soquelitinib could signal potential setbacks in development, possibly affecting investor confidence.
Drug DevelopmentA slight push in the timing of the announcement of clinical data for ciforadenant may raise concerns about the drug's efficacy or safety profile, impacting stock sentiment.
Financial HealthThe current cash runway remains a concern, indicating the company may face financial challenges, potentially leading to fundraising at unfavorable terms or operational cutbacks.